=

Cramer: This biotech stock could be worth over $100 billion on an FDA approval

111111111

October 30, 2019 0 Comments
Biogen, with a $54.1 billion market cap, “could be worth twice that if all goes well” with regulators, Jim Cramer says.
Tags:
Share: